Closing Figures: Kintara Therapeutics Inc (KTRA)’s Positive Finish at 0.12, Up 13.88

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

After finishing at $0.11 in the prior trading day, Kintara Therapeutics Inc (NASDAQ: KTRA) closed at $0.12, up 13.88%. In other words, the price has increased by $13.88 from its previous closing price. On the day, 7.15 million shares were traded. KTRA stock price reached its highest trading level at $0.127 during the session, while it also had its lowest trading level at $0.1153.

Ratios:

Our goal is to gain a better understanding of KTRA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.63 and its Current Ratio is at 0.63.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KTRA now has a Market Capitalization of 4739201 and an Enterprise Value of 14219201.

Stock Price History:

Over the past 52 weeks, KTRA has reached a high of $5.98, while it has fallen to a 52-week low of $0.08. The 50-Day Moving Average of the stock is 14.67%, while the 200-Day Moving Average is calculated to be -93.32%.

Shares Statistics:

The stock has traded on average 13.82M shares per day over the past 3-months and 3816070 shares per day over the last 10 days, according to various share statistics. A total of 55.30M shares are outstanding, with a floating share count of 55.20M. Insiders hold about 0.19% of the company’s shares, while institutions hold 0.40% stake in the company. Shares short for KTRA as of 1711584000 were 658896 with a Short Ratio of 0.05, compared to 1709164800 on 2191675. Therefore, it implies a Short% of Shares Outstanding of 658896 and a Short% of Float of 1.6900001000000002.

Earnings Estimates

A comprehensive evaluation of Kintara Therapeutics Inc (KTRA) is underway, with the input of Coterra Energy Inc. analysts contributing to its current rating.The consensus estimate for the next quarter is $0.66, with high estimates of $98.11 and low estimates of $85.28.

Most Popular

[the_ad id="945"]